Amisulpride 50mg tablets

Land: Storbritannia

Språk: engelsk

Kilde: MHRA (Medicines & Healthcare Products Regulatory Agency)

Kjøp det nå

Last ned Preparatomtale (SPC)
20-05-2020

Aktiv ingrediens:

Amisulpride

Tilgjengelig fra:

Creo Pharma Ltd

ATC-kode:

N05AL05

INN (International Name):

Amisulpride

Dosering :

50mg

Legemiddelform:

Oral tablet

Administreringsrute:

Oral

Klasse:

No Controlled Drug Status

Resept typen:

Valid as a prescribable product

Produkt oppsummering:

BNF: 04020100; GTIN: 5060222600520

Informasjon til brukeren

                                LOGO ACCORD
AMISULPRIDE 50MG, 100MG, AND 200MG TABLETS
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
•
IF YOU HAVE ANY FURTHER QUESTIONS, ASK YOUR DOCTOR, PHARMACIST OR
NURSE.
•
THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU ONLY. DO NOT PASS IT ON TO
OTHERS. IT MAY HARM
THEM, EVEN IF THEIR SIGNS OF ILLNESS ARE THE SAME AS YOURS.
•
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet.
WHAT IS IN THIS LEAFLET: _ _
1.
WHAT AMISULPRIDE TABLETS ARE AND WHAT THEY ARE USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AMISULPRIDE TABLETS
3.
HOW TO TAKE AMISULPRIDE TABLETS
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE AMISULPRIDE TABLETS
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT AMISULPRIDE TABLETS ARE AND WHAT THEY ARE USED FOR
Amisulpride tablets
contain the active substance amisulpride which belong to a group of
medicines called benzamide
antipsychotics. These work by improving thoughts, feelings and/or
behaviour when these are disturbed
in certain medical conditions.
Amisulpride tablets may be used in the treatment of acute (severe or
sudden) and chronic (ongoing or
long-term) schizophrenia, a condition where certain symptoms become
very noticeable. These include
feeling, hearing or seeing things that aren’t really there
(hallucinations), having a strong false belief
despite evidence against it (delusions), inability to think normally,
and feeling emotional, disinterested
or withdrawn.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE AMISULPRIDE TABLETS
DO NOT TAKE AMISULPRIDE TABLETS IF YOU:
•
are
BREASTFEEDING
•
are allergic to amisulpride or any of the other ingredients of this
medicine (listed in section 6) have
a
TUMOUR
that depends on prolactin (a hormone produced by the pituitary gland)
or
BREAST CANCER
•
have
PHAEOCHROMOCYTOMA
(a tumour of the adrenal gland causing high blood pressure)

                                
                                Les hele dokumentet
                                
                            

Preparatomtale

                                SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Amisulpride 50mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50mg Amisulpride
3
PHARMACEUTICAL FORM
Tablet
White to off-white round tablets with break line on one side and
‘50’ on other.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Amisulpride 50mg Tablets are indicated for the treatment of acute and
chronic
schizophrenic disorders, in which positive symptoms (such as
delusions,
hallucinations, thought disorders) and/or negative symptoms (such as
blunted
affect, emotional and social withdrawal) are prominent, including
patients
characterised by predominant negative symptoms.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
For acute psychotic episodes, oral doses between 400 mg/d and 800 mg/d
are
recommended. In individual cases, the daily dose may be increased up
to 1200 mg/d.
Doses above 1200 mg/d have not been extensively evaluated for safety
and therefore
should not be used. No specific titration is required when initiating
the treatment with
amisulpride. Doses should be adjusted according to individual
response.
For patients with mixed positive and negative symptoms, doses should
be adjusted to
obtain optimal control of positive symptoms.
Maintenance treatment should be established individually with the
minimally
effective dose.
For patients characterised by predominant negative symptoms, oral
doses between 50
mg/d and 300 mg/d are recommended. Doses should be adjusted
individually.
Amisulpride can be administered once daily at oral doses up to 300 mg,
higher doses
should be administered bid.
The minimum effective dose should be used.
_Elderly: _
The safety of Amisulpride has been examined in a limited number of
elderly patients.
Amisulpride should be used with particular caution because of a
possible risk of
hypotension or sedation. Reduction in dosage may also be required
because of renal
insufficiency.
_Children: _
_ _
The efficacy and safety of amisulpiride from puberty to the age of 18
years have not
been e
                                
                                Les hele dokumentet
                                
                            

Søk varsler relatert til dette produktet